• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet sales grow 22% in Q1

May 4, 2018 By Sarah Faulkner

Insulet omnipodInsulet (NSDQ:PODD) topped estimates on Wall Street yesterday with its first-quarter results, topping analysts’ sales expectations by $1.9 million.

The Billerica, Mass.-based company reeled in its losses, posting a net loss of -$6.6 million, or -11¢ per share, on sales of $123.6 million for the 3 months ended March 31, for bottom-line growth of 34.2% on sales growth of 21.5% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -11¢, ahead of consensus on The Street, where analysts were looking for sales of $121.7 million.

“We are expanding our opportunities for growth and driving continued operational excellence,” chairman & CEO Patrick Sullivan said in prepared remarks. “We have significantly expanded market access for Omnipod, made substantial progress on our innovation roadmap, and strengthened our global commercial footprint. We are building on last year’s momentum and look forward to another year of substantial growth and achieving positive operating income in 2018 for the first time inInsulet’s history.”

Insulet said it expects to post sales of $565 million to $580 million for the full year, up from a prior range of $560 million to $580 million.

PODD shares closed at $87.09 apiece yesterday, up +0.1%.

Analysts noted that Insulet’s sales performance points to the strong adoption of the company’s insulin delivery device.

“PODD is building a foundation for sustainably strong double-digit sales growth, continuing to develop the pipeline from the upcoming 2H18 Dash PDM (personal diabetes manager) launch to a Type 2 product and the Horizon AP (artificial pancreas), both of which will come to market over the next few years,” Leerink partners Danielle Antalffy and Rebecca Wang said in a note to investors.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS